<DOC>
	<DOCNO>NCT00932217</DOCNO>
	<brief_summary>To evaluate difference incidence febrile episodes patient undergo stem cell mobilization chemotherapy filgrastim versus chemotherapy lenograstim . A febrile episode consider : body temperature &gt; 38°C two measurement 24 hour interval 6 hour least two measurement .</brief_summary>
	<brief_title>Study Incidence Febrile Episodes During Stem Cells Collection After Chemotherapy Patients With Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>1 . Age &gt; 18 &lt; 70 year 2 . Diagnosis multiple myeloma 3 . ECOG &lt; 2 evaluated baseline , induction chemotherapy 4 . Indication mobilization high dose cyclophosphamide chemotherapy 5 . Normal blood count : neutrophil &gt; 1500/μl ; platelet &gt; 100.000/μl ; hemoglobin &gt; 10 g/dl . 6 . Liver renal function : SGOT/AST , SGPT/ALT ; bilirubin &lt; 1.5 time upper limit normal range ; creatinine &lt; 2 time upper limit normal range . 7 . Interval previous induction chemotherapy high dose chemotherapy 30 60 day 8 . ECG e/o Echocardiogram within age relate normal range 9 . Negative HCV HbsAg 10 . Must willing able fill patient 's diary 11 . Written inform consent 1 . Documented and/or suspected infection 2 . Uncontrolled concurrent illness 3 . Documented cardiac dysfunction</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2009</verification_date>
</DOC>